Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Solid Tumors 1Sarcoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Liver Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 9Temozolomide 7Radiotherapy 6Magnetic Resonance Spectroscopy 5Filgrastim 5Cisplatin 5Carboplatin 5antineoplaston AS 2-1 4antineoplaston A10 4Etoposide 4sargramostim 3Vincristine 3Thiotepa 3Melphalan 3Automobiles 3fludarabine 2aldesleukin 2Thalidomide 2Surveys and Questionnaires 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Eflornithine 2Donepezil 2Carmustine 2Biopsy 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2trifluridine tipiracil drug combination 1trametinib 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroectodermal Tumors, Primitive × TH 302 × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡